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WRN (Werner) protein is a member of the RecQ family showing helicase and 
exonuclease activity. WRN protein may lose function upon mutation and causes 
Werner syndrome (WS) which is an autosomal recessive, cancer-prone and premature 
aging disease. ATM (Ataxia-Telangiectasia mutated) protein initiates a signaling 
pathway in response to DNA double strand breaks (DSBs). Genomic disorder ataxia-
telangiectasia (A-T) is associated with defective ATM. WRN protein is involved in 
ATM pathway activation when cells are exposed to DSBs associated with replication 
fork collapse. Because the Mre11-Rad50-Nbs1 (MRN) complex, a sensor of DSBs, is 
known to interact with WRN and ATM, we investigated whether the MRN complex 
mediates the WRN-dependent ATM pathway activation.  In this study, we employed 
short-hairpin RNA to generate WRN- and Nbs1-deficient U-2 OS (osteosarcoma) 
cells. Cells were treated with clastogens which induce collapsed replication forks, 
  
thus provided proof for whether WRN facilitates ATM activation via MRN complex. 
This study serves as a basis for future investigation on the correlation between ATM, 
MRN complex and WRN, which will ultimately help understand the mechanism of 
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Chapter 1: Literature review 
1.1 The ATM-mediated DNA-damage response 
 
Cancer is a major cause of death worldwide. In year 2007, cancer accounted for 7.9 
million deaths which were around 13% of all deaths (WHO, 2009). Disequilibri m of 
genome stability in the form of genomic alteration, ranging from single-nucleotide 
substitutions to chromosomal aberrations, leads the way to cancer. Although DNA 
mutation is crucial to genetic variability in germ line, genomic alter tion in somatic 
cells is malignant. As genome stability continues to be impaired, a series of genomic 
aberrations will occur. Cells possess a strict system to safegu rd such changes (Levitt 
& Hickson, 2002). 
 
Replication errors, chemical changes in DNA components and normal DNA
transactions all cause sequence alteration. However, the greatest d mage to DNA is 
caused by DNA altering agents (Hoeijmakers, 2001). DNA altering agents could be 
either endogenous (cellular metabolism products) or exogenous (environmental 
factors). These agents damage DNA and affect proper function of normal protein, 
which in turn transforms cells into malignant states. In response t the damages, cells 
defend themselves by choosing to either correct DNA alteration or i itiate apoptosis 
(programmed cell death). The mechanism of how cells choose to urvive or die 
attracts great research efforts. It is also related to the purpose of this study and will be 




1.1.1 DNA-damage response 
 
DNA damage induced by endogenous or exogenous reagents causes differ nt forms 
of lesions including formation of covalent adducts with DNA and oxidative damage 
to bases and backbone of DNA (Norbury and Hickson, 2001). Some of the lesions 
cause cell death while others have the consequences from cellular malfunction to 
malignant transformation. It is recently clearer that cells have a signaling network that 
encompasses different processes including DNA-damage repair (Shiloh, 2003), cell-
cycle checkpoint (Amundson et al., 2001; Sesto et al., 2002) or cell apoptosis 
(Norbury and Hickson, 2001). 
 
1.1.1.1 Cell-cycle checkpoints 
 
Cell cycle checkpoints are signal transduction programs that link cell cycle phases in 
an error free manner. Cell cycle checkpoints preserve genomic stability by means of 
recognizing damage, initiating and coordinating repair in times of replication stress 
(Bartek et al., 2004). During checkpoints, cell cycle progression is temporarily halted 
to allow damage repaired or cellular functions completed. There are fou  different 
DNA damage checkpoints that cells employ: G1-S, S-M, G2-M and S. The G1-S, S-
M and G2-M arrest the cell cycle until damage is repaired whereas the replication is 






Figure 1.1 Cell cycle and DNA damage checkpoints. Cell spends time in G2 phase for 
normal cell growth. In M phase mitosis happens and two copies of DNA separat . In 
S phase nuclear division happens. 
 
The G1-S checkpoint checks the integrity of genome for entry into the S phase and 
allows the cell to repair damage, if any, during G1 phase. Cells in G1 contain only 
one copy of the genome so that there is no correct template for damage repair. At this 
time error prone methods such as non-homologous end joining (NHEJ) are inevitable 
options and G1-S checkpoint can initiate cell apoptosis to avoid passing on errors. 
 
The G2-M checkpoint halts cell mitosis under DNA damage pressur, ensuring that 




critical because two copies of genome make G2 a perfect time to repair dam ge. 
 
Unlike the G2-M checkpoint, the S-M checkpoint arrests mitosis in another way. This 
checkpoint is initiated when replication discontinues due to nucleotide depletion or 
polymerase malfunction. This checkpoint ensures that replication is fully completed 
before chromosome segregation. Any attempt to segregate with uncompleted 
replication is stalled by this checkpoint. 
 
The fourth checkpoint, the S phase checkpoint performs its task to slow down DNA 
replication in response to DNA damage. This stage of cell cycle is specially 
vulnerable as complicated metabolism and precise replication are required. Compared 
to the other three checkpoints, the S-phase checkpoint slows down rather th n totally 
stops replication process in the presence of damage (Rowley et al., 1999). Study on 
this checkpoint is one of the focuses of this research. 
 
1.1.1.2 DNA double strand breaks 
 
DNA double strand breaks (DSBs) are most dangerous and particularly effective 
among all kinds of DNA lesions to initiate finely-tuned DNA-damage response 
pathways whereas there is a highly conserved, sophisticated signaling network, 
existing from yeast to mammal, in response to DSBs (Shiloh, 2003). DSBs are 
extremely cytotoxic as they occur when the two complementary DNA double helix 




juxtaposed to each other by chromatin structure and base-pairing (Jackson, 2002). 
DSBs can follow normal genomic transactions (Bassing and Alt, 2004). However 
they are also introduced by oxygen radicals, ionizing radiation and radiomimetic 
chemicals.  
 
Cells possess a complex signaling network in response to DSBs controlling a number 
of cellular systems. Activation of cell-cycle checkpoints is a part of the network. 
While cell cycle is temporarily halted or slowed down, significant changes take place 
in cells including gene expression, protein function and other physiological processes 
to assess DNA damage and initiate repair (Latella t al., 2004). DNA repair 
mechanisms are another hallmark of the network. NHEJ (non-homologous end 
joining) and HR (homologous recombination) are the two main mechanisms used by 
eukaryotic cells to repair DSBs (Shiloh, 2006). NHEJ is a ligation process effective 
throughout the cell cycle and HR occurs between paired chromatids in the late S and 
G2 phases of the cell cycle. 
 
1.1.1.3 The three-tiered signaling response to DSBs  
 
There is increasing evidence showing that the DSB signaling cascade is composed of 
three kinds of proteins. ‘Sensors’ are proteins that sense DNA damage and convey 
signal to a group of proteins called ‘transducers’. These transducer  a t as signal 
magnifiers and in turn transmit the signal to functional proteins called ‘effectors’ in 





Several typical and well-studied sensors are the mammalian MRN (Mre11-Rad50-
Nbs1) complex, p53-binding protein 53BP1, tumor suppressor protein BRCA1 and 
mediator of DNA-damage checkpoint protein 1 (MDC1), all of which are recruited 
swiftly to DNA-damage site (Shiloh, 2006). In addition to their DNA processing 
function, they are all responsible for conveying early DNA-damage si nal to 
downstream transducers. MRN complex is a target protein of this study and will be 
introduced in detail later. 
 
The nuclear protein kinase ATM (ataxia-telangiectasia mutated) is a primary 
transducer of DSB signal. It in turn phosphorylates quite a number of downstream 
substrates in different damage response pathways (Kurz and Lees-Miller, 2004). The 
name comes from the genomic instability syndrome ataxia-telangictasia (AT). 
Symptoms of this syndrome are immunodeficiency, radiation sensitivity, cerebellar 
degeneration and cancer predisposition, which unveils the relationship between 
maintenance of genome stability and cancer prevention (Shiloh, 2003). ATM belongs 
to a protein family named ‘The PI3K-like protein kinases (PIKKs). Mutated ATM 
gene was obtained from ataxia-telangiectasia syndrome patients in 1995 (Savitsky et 
al., 1995). Cell lines from such patients are deficient in response to DSBs and show 
defect in almost all DSBs responses (Shiloh, 2001), which places ATMin an 





1.1.2 The PI3K-like protein kinases 
 
Most PIKKs, as they are named, possess the lipid kinase phosphatidylinositol 3-
kinase (PI3K) motifs. So far six family members have been found in mammal: ATM, 
ATR (Rad3-related), hSMG-1, mTOR (also known as FRAP), DNA-PK (the catalytic 
subunit of the DNA-dependent protein kinase) and TRRAP (Shiloh, 2006). Most of 
the family members also contain domain that are typical of serine/theronine kinase 
activity (Figure 1.2). Four of the PIKKs, DNA-PK, ATM, ATR and hSMG-1 are 
related to mammalian DNA damage response (Sesto et al. 2002, Abraham, 2001 and 
Durocher, 2001). DNA-PK and ATM response for the most part to DSBs whereas 
ATR and hSMG-1 response primarily to UV light induced replication arrest as well as 
to DSBs and stalled replication forks. ATM and ATR share some substrates in the 






Figure 1.2 Mammalian PIKK family. The number of amino acids is indicated on the 
right. The PI3K domain contains the catalytic site for the family. 
 
The functional relationship between ATM and ATR remains largely unknown. There 
is mounting evidence showing that ATM and ATR are triggered independently in 
response to DSBs and phosphorylate substrates in a redundant fashion (Shiloh, 2006). 
However, recent studies also show that part of ATR function as a DSB sensor requires 
ATM. ATR is dependent on ATM to bind to DSB sites and not until the binding occur 
can ATR phosphorylate downstream substrates. Other ATR functions such as respon e 
to UV light induced DNA lesions, however, do not require ATM assistance (Jazayeri 









When DSB forms, sensor proteins are first recruited to DNA damage sites. 
Understanding of the early stage of response is a key to understanding the whole 
repertoire. The MRN complex, as stated before, is the first recruit to the damaged 
sites (Lukas et al., 2004 and Lou et al., 2006). Then come MDC1 and 53BP1, in turn. 
MDC1 is responsible for conglomerating MRN complex and 53BP1 together to the 
damaged chromatin (Lukas et al., 2004 and Bekker-Jensen t al., 2005). Meticulous 
imaging analysis shows that ATM is spatially organized together with the MRN 
complex, MDC1 and 53BP1 in DSB flanking chromatin subcompartments (Bekker-
Jensen et al. 2006). 
 
In the past, Nbs1, a component of MRN complex as well as MDC1 and 53BP1 were 
assumed to be substrates of ATM phosphorylation (Kurz and Lees-Miller, 2004). 
Mounting new evidence illustrates a different picture: in addition o their effectors’ 
role, they also acts as sensors that trigger transducer ATM. Thusa signal 
amplification model is established in a way that damage signal is enhanced by cyclic 
interaction between these proteins (Lavin, 2004). 
 





When it is inert, ATM protein exist in the form of dimmers or multimers which 
disassociate to active monomer form during DNA damage (Bakkenist a d Kastan, 
2003). The second step of activation is autophosphorylation on Ser1981. Both of the 
two steps require MRN. It has been found that the MRN complex physicall  finds 
ATM by C-terminal domain of the Nbs1 protein (Falck et al., 2005 and You et al., 
2005). Of course, ATM activation also requires the contact of ATM-MRN 
conglomeration to DSB ends (Dupre et al., 2006). In addition to the MRN cyclic 
interaction, there is another protein that is recently found to attract ATM to the 
damage site in a similar cyclic fashion. γH2AX, which is a phosphorylation substrate, 
is shown to bind to BRCT domain of MDC1, thus enabling MDC1 to hold on to ATM 
(Lou et al., 2006). An ATM-MDC1 conglomeration is formed close to DNA flanking 
DSBs in such a way as to activate ATM and phosphorylate H2AX in the vicinity. 
 
After the autophosphorylation process, ATM protein undergoes further modification 
in the forms of phosphorylation and acetylation. The complete activation process of 
ATM involves a large number of proteins, only a few of which have been investigated. 
Two phosphatase, PP2A and PP5 are reported to interact with ATM during its 
activation (Goodarzi et al., 2004 and Ali et al., 2004). WRN (Werner syndrome) 
protein has been recently reported to be involved in ATM activation in response to 
interstrand cross-link-induced DSBs (Cheng et al., 2008). The WRN protein is also a 
target of this study and will be discussed in later chapters. 
 





There is a long list of known ATM effector proteins (Shiloh, 2006). However, the list 
is far from complete. The good news is the investigation of known proteins in the 
network leads us to understand the meticulously controlled strategies used by ATM. 
 
The first strategy is that ATM target the same endpoint by means of different 
pathways. For example, at least five pathways mediated by ATM are involved in the 
intra-S checkpoint. The multifunctional Nbs1, component of MRN, is phosphorylated 
by ATM and involved in the checkpoint (Lim et al., 2000). FANCD2 protein, which is 
phosphorylated on Ser222 is also found to be related to this checkpoint (Taniguchi et 
al., 2002). In addition, BRCA1, SMC1 (structural maintenance of chromosome 1) 
protein, CHK1/CHK2 proteins are also activated by ATM and take car of several 
checkpoints (Kim et al., 2002, Mailand et al., 2000, Falck et al., 2001 and Falck et al., 
2002).  
 
Further more, another key strategy of ATM mediation is a same effector could be 
reached from different ATM mediated mechanisms in a redundant mner. For 
example, p53 protein, a main target of ATM activation is directly phosrylated by 
ATM on Ser15 (Banin et al., 1998). ATM also activates CHK2 as stated above which 
in turn phosphorylated p53 on Ser20 (McGowan 2002 and Bartek et al., 2001). Other 
ATM dependent phosphorylation site of p53 on Ser9 and Ser 46 are also published 
(Saito et al., 2002). ATM phosphorylates p53 inhibitor MDM2, preventing the nuclear 




and Maya et al., 2001). Another p53 inhibitor Mdmx also undergoes ATM dependent 
phosphorylation which induces degradation of p53 (Pereg t al., 2005 and Chen et al., 
2005).  
 
Of course, numerous substrates of ATM are protein kinases that are themselves able 
to activate downstream effectors and are in control of branches of pathways. CHK2 is 
a prominent example. It is found to phosphorylate p53, BRCA1, CDC25A and 
CDC25C. CHK2 mediated phosphorylation of CDC25C lead to cytoplasmic 
sequestration of CDC25C, which prevents activation of a number of proteins such as 
CDK1 (McGowan 2002 and Bartek et al. 2001). 
 
There is recently a new theory which may be complimentary to the existing effector 
model. The new theory (Goodarzi et al., 2008) correlates dynamic changes of 
chromatin to ATM signaling. The architecture of euchromatin is in such a loose form 
that repair factors are easy to access and manipulate DSBs. However, in 
heterochromatin, the nucleosome flexibility is limited by heteroch omatic factors like 
KAP-1, HP1, HDACs (Lavin et al., 2005; Ziv et al., 2006). ATM is required to 
phosphorylate these factors and decrease their interaction with heterochromatin, and 
therefore change condensed chromatin regions into open forms and allow the damage 
be repaired in an ATM dependent manner (Fernandez-Capetillo and Nussenzweig, 
2008) . 
 




cells respond to DNA damage. Each of the three tiers of the signalin  cascade 
provides ramification of research interests. In particular, elucidating how signal is 
passed on from MRN complex to ATM continues to be a major research direction. 
What is the conformation of this complex? How does the complex rush to the damage 
site? How does it change ATM from inert dimmers into activated forms? Some of the 
questions already have answers and some of them are still open. In next chapter of 
this review, some known and unknown aspects of MRN complex will be investigated.  
 
1.2  The key players that mediates ATM pathway activation 
 
Among all the proteins upstream or downstream ATM, some of them like p53 have 
been studied for decades, their function clarified, while the mechanism of some others,
although essential in the signal pathways, remain largely unknown. This thesi  study 
chose two factors, the MRN complex and WRN protein, from many and tries to 




The MRN complex was first identified in budding yeast as repai roteins composed 
of three subunits. Among them, Mre11 and Rad50 are highly conserved in all 
taxonomic kingdoms while Nbs1 homologues are only identified in eukaryotes: Xrs2 
in yeast and Nbs1 in vertebrate cells (van de Bosch et al., 2003). The conservation 




(Lee et al., 2003). Figure 1.3 illustrates that two Mre11s, two Rad50s and one Nbs1 
form a 2:2:1 stoichiometric MRN complex. Rad50 and Nbs1 are not directly bound to 
each other but to Mre11 instead (Williams et al., 2007). 
 
Figure 1.3 2:2:1 stoichiometric MRN complex structure. Two Mre11s, two Rad50s 
and one Nbs1 form a 2:2:1 stoichiometric MRN complex. Rad50 and Nbs1 are not 
directly bound to each other but to Mre11 instead 
 
1.2.1.1 MRN, its subunits and the function as a sensor of DNA DSBs 
 
As shown in Figure 1.4, Mre11 has five conserved phosphoesterase motifs forming 
the nuclease activity in its N-terminus and two DNA binding domains in its C-
terminus. It also contains Nbs1 binding domain near its phosphoesterase motifs and 
Rad50 binding domains in the C-terminus (D’Amours and Jackson, 2002). Rad50 
contains Walker A and Walker B motifs (ATPase domains) that bind together in the 
presence of ATP. In the middle of Rad50 there are CXXC sequences that bridge DNA. 




to Mre11 near Walker motifs (Williams et al., 2007). Nbs1 contains ATM and Mre11 
binding domains in the C-terminus and FHA (Forkhead Associated) and BRCT 
(Breast cancer C-Terminal) phosphopeptide interaction domains in the other end 
(D’Amours and Jackson, 2002). These two phosphorylation interaction domains are 
indispensible for DNA lesion recognition, S-phase checkpoint function and 
checkpoint phosphorylation of Nbs1 (Kobayashi et al., 2004; Horejsi et al., 2004). 
 
Figure 1.4 Known structural domains for the Mre11, Rad50 and Nbs1 proteins. The 
number of amino acids is indicated on the right. 
 
There are mounting evidence showing that MRN complex is rapidly recruited to DNA 
damage site (Lavin, 2007) independent of ATM association (Mirzoeva and Petrini, 
2001). It should also be noted that, during S phase, the complex binds to chromatin in 
the absence of DNA damage (Mirzoeva and Petrini, 2003). The dynamics of the 
binding is as follows: The coiled-coil regions of Rad50 fold in a shape to bring 
Walker A and B motifs in proximity to form a globular domain which binds DNA. 




consequently bridge two DNA molecule together (Hopfner et al., 2002). Upon 
binding to DNA, the parallel orientation of the coiled-coil regions favors inter-
complex association and inhibits intra-complex interaction (Moreno-Herrero et al., 
2005). Rad50 associates with Mre11 and Mre11 in turn associates with Nbs1 by the 
binding domains introduced in the leading paragraph. The association between Rad50 
and Mre11 stimulates the exonuclease and endonuclease activities of Mre11 (Paull 
and gellert, 1998; Trujillo and Sung, 2001) while the binding between Nbs1 and 
Mre11 initiates the endonuclease ability of the latter (Paull and gellert, 1999). 
 
It is evident that the initial event in recognizing and responding to DNA DSBs is the 
binding of MRN complex, which bridges broken ends together. However, there ar  
other proteins that facilitate such binding. For example, MDC1, a large nuclear 
protein, was shown to physically couple the complex to damage site. Mutations in 
some conserved motifs of MDC1 disrupt the accumulation of the MRN complex at 
DNA DSBs sites in vivo (Spycher et al., 2008). 
 
1.2.1.2 Activation of ATM by MRN complex 
 
It has been discussed briefly in the chapter 1 how ATM is recruited and rapidly 
activated. Here the complete investigation process will be introduced as well as some 
very important milestone experiments. These experiments are also very illustrating 





In order to prove MRN complex is upstream of ATM and is required for ATM 
activation, NBS (Nijmegan Breakage Syndrome) and ATLD (Ataxia-Tel ngiectasia-
like Disease) cells, both of which contain hypomorphic mutation in the complex 
subunits, are used as basis of studies. And ATM activation is determined either by 
autophosphorylation on Ser1981 or its capacity to phosphorylate downstream 
effectors in these studies. ATM activation was found to be retarded in both cells 
response to radiomimetic chemical neocarzinostatin treatment (Uziel et al., 2003). It 
has also been shown that an Nbs1 construct retaining ATM and Mre11 binding site 
could stimulate ATM activation in most NBS mutation cells (Digweed et al., 1999; 
Cerosaletti and Concannon, 2004; Falck et al., 2005). When Nbs1 protein lacks ATM 
binding site, in this case the NbFR5∆Atm expressed by NBS cells, ATM activation is 
dramatically reduced (Cerosaletti et al., 2006).  
 
Viral infection of cells was also used to investigate how MRN complex activates 
ATM. An end-joining of adenovirus genome resembles DNA damage. Results show 
that ATM is activated in end-joining regions (Carson et al., 2003) and degradation of 
MRN complex decreases the level of ATM autophosphorylation. 
 
There are also in vitro studies on the ability of MRN complex to acivate ATM (Lee 
and Paull, 2004, 2005). Baculovirus expressing MRN components was used in these 
studies, and a direct activation of ATM was observed by immunoprecipitation. 
Surprisingly, those studies further found that Mre11/Rad50 could hook ATM to DNA 





Consequently, there are emerging data suggesting that ATM is not recruited only by 
the C-terminus binding domain of Nbs1. In a study on Nbs1-knockout mice with 
BAC transgenes, a mutant carrying an Nbs1 transgene that lacks 20 amino acids in 
the C-terminus displayed normal ATM activation (Difilippantonio et al., 2007). The 
lack of an Nbs1 function seems to be remediated by other interaction between MRN 
components and ATM. Another experiment based on a mouse model of Nbs1 lacking 
24 amino acids in the C-terminal also showed normal ATM phosphorylation (Stracker 
et al., 2007). These findings are supported by data that ATM contacts different part of 
the MRN complex (Lee and Paull, 2004; Stracker et al., 2007), which points to a 
more complicated map of MRN complex mediated ATM activation. 
 
1.2.1.3 Nbs1 and its role in the DNA damage response 
 
Previously, it was mentioned that Nbs1 plays a role in the cyclic pathway of ATM 
mediated DSBs response, which is Nbs1 both serves as a sensor activating ATM and 
an ATM effector as well. It is why Nbs1 is chosen as the targe  protein of this thesis 
research. Here Nbs1 is picked out for more detailed introduction for the sake of 
understanding the rationale of research design. 
 
Nijmegan Breakage Syndrome (NBS) is a recessive autosomal inst bility disorder 
characterized by growth retardation, immunodeficiency and cancer predis osition 




chromosome 8q21-24 (Matsuura et al., 1998; Carney et al., 1998). The gene is 50kb 
in size and is transcripted to two mRNAs, 2.6kb and 4.8kb, respectively. Nbs1 gene 
encodes a protein of 754 amino acids which displays a low homology to yeast Xrs2 at 
both ends. As stated before, unlike Mre11 or Rad50, homologs of Nbs1 have not b en 
identified in archaebacteria or prokaryotes and are very unique only t  eukaryotic 
cells. 
 
The protein contains an N-terminus region, a central region and a C-terminus region. 
FHA and BRCT domains in the N-terminus are very conserved in eukaryotes and 
both related to cell cycle checkpoints or DNA repair. The FHA motif recognizes 
phosphorylation of the target protein (Durocher et al., 1999). The C-terminus region 
binds to Mre11 and has three possible nuclear localization signal sequenc s 
(Kobayashi et al., 2004). There are several SQ motifs in the central region of Nbs1. 
The serine residues at 278 and 343 are phosphorylated by ATM, which plays an 
essential role in the intra-S checkpoint (Wu et al., 2000; Tauchi et al., 2000). 
 
It has already been discussed in the previous sessions how Nbs1 take part in the MRN 
mediated ATM activation in response to DNA DSBs. However, Nbs1 has multiple 
roles which exceed beyond the range of ATM activation and will be introduced 
respectively here. 
 





10% of human histone H2A protein is the histone variant H2AX which is evenly 
distributed in chromatin. The phosphorylated form of H2AX, the γ-H2AX interacts 
with MRN complex through Nbs1 (Kobayashi et al., 2004). Evidences show that the 
direct interaction of γ-H2AX with Nbs1 is through the FHA/BRCT domains 
(Kobayashi et al., 2002; Cerosaletti and Concannon, 2003). This interaction is very 
important for the MRN complex form foci in response to DSBs as well as for other 
damage response proteins containing BRCT domains (Stewart t al., 2003; Bassing et 
al., 2002). 
 
HR repair and inter-chromosomal translocation 
 
Non-homologous end joining (NHEJ) and homologous recombination (HR) are two 
major pathways to repair radiation-induced DSBs. It has been shown in Nbs1-defient 
chicken cells that Nbs1 plays an indispensible role in HR rather than NHEJ repair 
(Tauchi et al., 2002). This result was also confirmed in mice study that NBS cells ar  
deficient in meiotic recombination and HR repair (Bassing et al., 2002). 
 
Whereas Nbs1 is not required in NHEJ, increased chromosomal transloc tions are 
observed in NBS cells, which is consistent with Nbs1 mutant mice study (Kobayashi 
et al., 2004). These data suggest that Nbs1 protein functions in suppression of inter-
chromosomal recombination.  
 





In vertebrates, cell cycle progression will be temporarily halted in response to DSB 
inducing agents until DNA damage is repaired. At least three pathways have been 
reported participating in the intra-S cell cycle checkpoint, two of which are Nbs1 
dependent: the ATM/Nbs1/SMC1 pathway (Kim et al., 2002; Yazdi et al., 2002) and 
the ATM/FANCD2 pathway (Nakanishi et al., 2002). In the first pathway, Nbs1 
phosphorylates SMC1 on Ser278 and Ser343. In the second pathway, the FANCD2 
phosphorylation requires the phosphorylation of Nbs1 on Ser343 by ATM. There is 
evidence showing that it is Mre11 binding domain instead of FHA/BRCT domains of 
Nbs1 taking part in the efficient induction of the intra-S checkpoint (Stewart et al., 
2003; Goldberg et al., 2003). G1 and G2 checkpoints may involve Nbs1, however the 
reports are controversial and the mechanism behind them remains unsolved 




There are a number of human disorders that belongs to a category of diseases called 
human premature aging disorders. These patients prematurely develop a variety of 
conditions which shows clinical characteristics seen in the normal aging process, for 
example, malignant neoplasms, type II diabetes mellitus and ocular cataracts (Yu et 
al., 1996). Therefore, it is quite understandable that studying human prematur  aging 





Werner syndrome (WS) is a rare autosomal recessive disorder that belongs to this 
disease category. WS patients display remarkable aging symptoms in early stage of 
life starting around puberty. Those symptoms are similar to those of more elderly 
individuals. In addition, some geriatric disorders such as hypertension or Alzheimer’s 
disease are not seen in WS. Moreover, WS displays symptoms that are not age related 
including reduced fertility, hypogonadism and short stature. Thus, WS has been 
regarded as a perfect model to study human premature aging disorders as well as to 
understand the mechanism of normal aging. The 162kDa Werner protein, known as 
WRN, is encoded by the gene defective in WS (Yu et al., 1996). In this chapter, the 
biochemical and catalytic characteristics of this protein will be introduced. Then the 
focus of the introduction falls into how WRN functions in DNA damage response 
pathways. 
 
1.2.3.1 WRN and the RecQ family of DNA helicases 
 
The WRN protein belongs to a category of DNA helicases called th  RecQ family. 
This widely expressed protein family are required for the maintenance of genome 
integrity (Mohaghegh and Hickson, 2001). Family members have been identified 
throughout eukaryotes while five of them are present in humans. This fam ly is 
characterized by a highly conserved ~400 amino acids helicase domain (Hickson, 
2003). For some ‘long form’ family members, there are flanking domains on both 
sides of the central helicases domain which are not quite conserved while other 




Figure 1.5 the human RecQ helicases family). 
 
Figure 1.5 The human RecQ helicases family. The number of amino acids is indicated 
on the right. 
 
The RecQ family are considered to be ‘caretaker’ tumor suppressors because studies 
on mutants find out that defects in the genes generate autosomal recessiv  disorders 
and an elevated incidence of cancer (Ellis et al., 1995; Yu et al., 1996; Kitao et al., 
1999). RecQ helicases are found to have dynamic subnuclear localizations nd bind 
to numerous partners under different cell growth conditions. Thus, they have multiple 
roles in DNA replication as well as in telomere maintenance (Hickson, 2003). The 




flanking domains and participates in a wide range of cellular activities. 
 
The WRN gene is located at position 8p12 on chromosome (Yu et al., 1996). The 
WRN protein possesses a DNA-dependent ATPase activity that unwinds double 
strand DNA in the 3’→5’ direction (Shen et al., 1998). Besides, it is the only known 
protein of this family to possess a 3’→5’ exonuclease activity (Shen et al., 1998). 
This activity is initiated at a duplex blunt if the substrate also contains bubble, loop or 
Holiday junction (Shen and Loeb, 2000). Like other family members, the conserved 
RecQ helicase domain is located centrally. There is a putative ranscription activation 
domain between the helicase and exonuclease domains. Thus the helicase and 
exonuclease activities are physically separated from each other and don’t functionally 
interfere with each other. The C-terminal region accommodates nuclear localization 
element (Fry, 2002) and the RecQ conserved RQC domain containing localization 
signal-dependent nuclear targeting sequence. In addition, a HRDC (Helicase and 
RNaseD C-terminal) domain considered to participating DNA binding also exists in 
the C-terminal region (Bernstein et al., 2003). Please refer to Figure 1.5 above for a 
schematic representation of the WRN domains. 
 
1.2.3.2 Multiple roles for WRN 
 
Thanks to its bifunctional nature, the WRN protein acts as intermediates in DNA 
replication, telomere maintenance and DNA damage response. Given the large 




The pathways incorporating WRN could only be delineated partially b sed on some 
well studied WRN interactors (Opresko et al., 2003 also see Figure 1.6 for in vivo 
functions of WRN and interactors). 
 
Figure 1.6 WRN and interactors. These interactors take part in a variety of DNA 
metabolism pathways and a precise map of WRN cellular function is still not clear. 
 
WRN is a part of the 17S DNA replication complex and interacts with topoisomerase 
I (Lebel et al., 1999). WRN interacts with topoisomerase I through the two terminals 
and facilitates topoisomerase I to relax negatively supercoiled DNA, which explains 
why WS cells are sensitive to camptothecin, a DNA topoisomerase I inhibitor, during 
G2 and S phase (Laine et al., 2003). WRN associates with replication protein A (RPA) 
which is necessary for DNA replication (Wold, 1997). RPA facilitates WRN to 
unwind longer substrates while WRN alone can only unwind much shorter partial 
duplexes (Brosh et al., 1999). RPA may help WRN to cope with rotational rigidity 
during unwinding process by restraining it at the single-strand/double strand junction 




major replicative DNA polymerase δ. Studies show that the C-terminal region of 
WRN interacts with the p50 and p125 subunits of DNA polymerase δ and also co-
localizes with the two subunits in the nucleolus (Szekely et al., 2000). Another 
replication protein that associates WRN is the FEN-1 protein (Brosh et al., 2001). 
WRN interacts with FEN-1 through its RQC domain as mentioned above. This 
interaction greatly enhances nucleolytic activity of FEN-1 (more than 80 fold). The 
cleavage function of FEN-1 is also increased through combination with WRN. 
 
The second important role for WRN is maintenance of genomic stability in the 
presence of DNA damage. Not only the WRN/FEN-1 complex discussed above is 
involved in non-homologous DNA end joining (NHEJ) (Wu et al., 1999), a Ku-DNA-
PK complex has also been reported to interact with WRN in repairing DNA DSBs 
caused by ionizing radiation, genotoxic chemicals and physiological oxidative stress 
(Featherstone and Jackson, 1999). The complex comprises of DNA-PKcs and 
Ku70/Ku80 heterodimer. The heterodimer interacts with the both the C and N 
terminal of WRN. It is possible that the Ku activates WRN to remove some 
replication blocks (Ozgenc and Loeb, 2005) and also DNA-PKcs to phosphorylate 
WRN and negatively regulate its end processing during NHEJ (Opresko et al., 2003). 
In addition, WRN and Ku70/Ku80 participate in the formation of a cellular trimeric 
complex with poly (ADP-ribose) polymerase-1 known as PARP-1 (Li et al., 2004). 






Biochemical and genetic evidence suggest that WRN participate in the homologous 
recombinational (HR) repair pathway as well as the base excision repair (BER) which 
are both very important in response to DNA damage. WRN participation in HR is 
dependent on Rad51 (Opresko et al., 2003). Direct physical interaction between 
WRN and the MRN complex containing Rad51 has been found (Cheng et al., 2004). 
BER is an essential pathway to cope with DNA lesions such where WRN may also 
participates. It forms a complex with apurinic/apyrimidinic endonuclease (APE-1), a 
key regulator in early BER (Ahn et al., 2004). The helicase activity of WRN is 
required for DNA polymerase β strand displacement synthesis on a nicked BER 
intermediate (Harrigan et al., 2006). 
 
Loss of telomeric DNA triggers replicative senescence. WS cell culture experiment 
shows WS fibroblast cells are more exposed for telomere fragment lost than normal 
fibroblast cells (Orren, 2006). The WRN/Ku, WRN/DNA-PK and WRN/MRN 
complex interaction are not only important of DNA damage response but also 
essential in telomere metabolism (Opresko et al., 2003). In addition, WRN protein is 
found to co-localize with relomeric repeat binding proteins TRF1 and TRF2 (Yeager 
et al., 1999). RQC domain of WRN has been reported to physically interact with 
TRF2 (Opresko et al., 2002). The WRN exonuclease digestion of the telomeric 
repeats is limited by the association of TRF2 and TRF1 (Opresko et al., 2004). Recent 
evident shows both enzymatic activities of WRN are needed to suppres telomeric-






1.2.3 ATM/MRN and ATM/WRN in response to DNA damage 
 
Although the interactions between ATM/MRN and ATM/WRN in the presence of 
DNA damage are not clarified very clearly, understanding the so far known 
interactions shed light on the hypothesis and design of this thesis study. 
 
1.2.3.1 ATM/MRN complex interdependence model in response to DNA damage 
 
As discussed above, it could be conclude that the MRN complex and ATM are 
interdependent in recognizing and signaling DNA DSBs. Berkovich et al. (2007) 
provided a relatively clearer picture of the dynamics of proteins involved in this event 
(Figure 1.7). A binding of the MRN complex to damaged DNA happens initially 
followed by recruitment of ATM in the break and surrounding area in n Nbs1 
dependent manner, whereas inactive ATM is unable to bind to DNA DSBs. At least 
three autophosphorylation sites (Ser1981, Ser 367 and Ser1893) have been found to 
be inherent post translational parts of the activation mechanism. As ATM is displaced 





Figure 1.7 Early events in DSB response. The MRN complex is the first to be 
recruited to DSB site followed by stimulation of ATM dimmers. After binding to 
MRN, ATM initiates its effectors and downstream responses. 
 
1.2.3.2 ATM/WRN interdependence model in response to DNA damage 
 
According to the previous chapters, ATM and WRN are proved to be key regulators in 
response to DNA damage independently. Also there is report suggesting that RecQ 
helicases may be implicated in ATM activation (Davalos et al., 2004). There is still 
limited evidence supporting the interaction between ATM and WRN. It was not until 




downstream effectors in response to DNA interstrand cross-link-induced DSBs 
(Cheng et al., 2008). Using the same cell models, this study also found WRN and 
ATM cooperates in a PUVA-induced intra-S-phase checkpoint. Taken together, WRN 
is required for ATM activation under the condition of replication-dependent DSBs 
while resolve recombination intermediates on the other hand. Post-tran la ional 
phosphorylation of WRN regulates the multiple roles of this protein (Sidorova et al., 
2008). 
 
1.2.4 Mutations in ATM, MRN, and WRN in humans 
 
In this chapter, all known mutations in the three protein/protein complex will be 
reviewed to provide a more vivid and historic picture of this research study. 
 
Before ATM gene was found in 1995, researcher used to propose that AT disease was 
caused by multiple genes because this gene is so pleiotropic in its clin cal features. 
Patients were categorized into four complementation groups based on clinical 
characterization while researchers thought they might be determined by four different 
genes (Jaspers et al., 1988). Further study found that there was only one gene behind 
all four complementation groups. This gene was found on chromosome 11q22-23 by 
positional cloning (Savitsky et al., 1995). The complete sequence of ATM (150,000 nt; 
66 exons) was found by the same research group (Savitsky et al., 1995). It was also 
found that loss of ATM function in AT patients is due to different alternations which 
caused premature truncations or in frame amino acids deletions consequently (Table 




researchers have been trying to establish phenotype-genotype relationship in 
emerging ATM mutation because mutation status in ATM alleles is an important 
determinant of cellular and clinical features (Austen et al., 2007; Broeks et al., 2008).  
 
Mutation  Phenotype ATM protein levels % 
875C→T Slow progression of classic AT symptom Trace 
3576G→A Extended longevity 5 
5435del3 Late onset of ataxia 12 
6047A→G Slow progression of classic AT symptom 4 
7271T→G Extended life span 100 
9139C→T Decreased radiosensitivity 16 
8030A→G Mild neurological features <10 
8494C→T Slow progression of classic AT symptom 11 
Table 1.1 Phenotype and genotype relationships of AT variants (Rotman and Shiloh, 
1998; Chun and Gatti, 2004) 
 
Given the relationship between ATM and Nbs1 protein, NBS disease shar a variety 
of clinical features with AT in such a degree that NBS was once thought to be a 
variant of AT (Shiloh 1997). Studies later revealed that some then-AT diseases were 
actually caused by another gene located on chromosome 8q21 (Saar et al., 1997). 
Nbs1 gene was soon identified by positional cloning to have a 4386bp cDNA 
sequence and a molecular mass of 95kDa (Matsuura et al., 1998; Varon et al., 1998). 




Nbs1 gene was identified, unlike ATM mutations, research has been focused on 
several dominant ones. The 657del5, the I171V and the R215W mutations are 
believed to be responsible for the majority of NBS cases (Nowak et l., 2008). These 
mutations of the Nbs1 gene were all found to increase cancer susceptibility 
(Bogdanova et al., 2008; Roznowski et al., 2008; Masi et al., 2008). 
 
Although different degree of ATM mutation could be used to explain AT type 
syndromes which might be milder or severer than classic AT disease, some AT like 
syndromes are not caused by ATM mutation (Hernandez et al., 1993). ATLD, Just like 
NBS though rarer, is one kind of AT like disease that is caused by mutation in another 
gene: Mre11 (Stewart et al., 1999). ATLD gives rise to slower progress of AT 
symptom in early stage of development and does not cause telangiectasia. Table 1.2 
shows the difference between AT, NBS and ATLD in detail. Two mutations: 350 
A→G and 1897C→T, are responsible for ATLD (Taylor and Byrd, 2004). Because 
Mre11 mutation induced ATLD is very rare, there is only very limited report on new 
mutations in ATLD patient. Only two 630G→C mutation cases were reported in 
Arabian population (Alsbeih et al., 2008) whereas there are reports showing new 
mutation in cultured cells lines (Wen et al., 2008). 
 
Clinical features AT ATLD  NBS 
Telangiectasia + - - 
Ataxia + + - 
Reduced immunoglobulin levels + - + 




Microcephaly - - + 
Craniofacial abnormalities - - + 
Congenital malformations - - + 
Dysarthria + + - 
Raised serum AFP level + - - 
Table 1.2 Clinical features of AT, ATLD and NBS (Taylor and Byrd, 2004). + 
presence of feature, - absence of feature. 
 
As a partial model of human aging, investigation into WRN gene has long drawn 
research interests. The location of the gene was initially narrowed to chromosome 
8p12 by linkage analysis (Goto et al., 1992). A WRN gene was identified also by 
positional cloning and composed of 1432 amino acids (Yu et al., 1996). Like ATM 
protein, the large size of WRN gene makes possible a high number of mutations 
including nonsense, frameshift or insertion/deletion. However, all those mutations 
have only two kinds of truncated protein products which either fail to localize to the 
nucleus properly or become unstable in enzymatic activities (Opresko et al., 2007; 
Ozgenc and Loeb, 2005). 
 
1.3 Hypothesis and concept of this thesis work 
 
The idea of this research study was illustrated by a 2008 paper on WRN and ATM 
interaction in response to DNA DSBs (Cheng et al., 2008). In this paper, WRN was 
found to be required for ATM activation in response to agents that produce interstrand 




we hypothesize that WRN might stimulate ATM activity with the help of MRN 
complex. 
 
In designing the experiments, we chose to knockdown Nbs1 expression with Nbs1 
short-hairpin RNA (shRNA) because Nbs1 serves as an central role in the MRN 
complex and Nbs1 shRNA is available from another research group in Australia and 
proven to be quite effective (Zhong et al., 2007). Meanwhile, WRN knockdown cell 
line and its control are already available in our lab. Thus, all the experiments are 
based on four cell lines as shown in Table 1.3. 
 
 NW WRN NC CON 
Nbs1 - + - + 
WRN - - + + 
Table 1.3 four cell lines established from WRN and Nbs1 shRNA. + normal gene 
expression; - knocked down gene expression. ). NC: Nbs1/WRN control; NW: 
Nbs1/WRN; C: WRN control; W: WRN. 
 
First, western blot analysis is used to confirm the genetic chara teristics of the four 
lines. Pictures of cell morphology are taken and compared. Then cell survival assays 
are conducted to compare the growing ability of four different lines. 
 
DNA damaging agents Camptothecin (CPT) hydroxyurea (HU), both producing 




et al.; Lundin et al., 2002), are selected to treat the four cell lines in a timely anner 
according to Cheng et al’s paper (Cheng et al., 2008). Aphidicolin (Aph) is selected 
for control treatments because it inhibits replication by inhibiting DNA polymerase 
therefore also halts cell cycle progression in early S phase appearing similar to the 
effects of CPT or HU (Saleh-Gohari et al., 2005). 
 
In completing this research, we hope to be able to investigate two questions: Whether 
MRN complex is involved in WRN mediated S phase checkpoint and whether the 











Chapter 2: Materials and Methods 
 
2.1 Materials 
2.1.1 Bacterial strain, cell strain and vectors 
 
Bacteria Description References 
Escherichia coli DH5α 
a recombinant-deficient amber 
suppressing strain used as host of gene 
cloning 
Hanahan, 1983 
Cell Description References 
U-2 OS an osteosarcoma cell line Cheng t al., 2006 
Plasmid vectors Description References 
pSilencerTM 3.1-H1 hygro 
vector 
vector expressing WRN shRNA Ambion Inc. 
pCIpur vector vector expressing Nbs 1 shRNA Zhong et al., 2007 
 Table 2.1 Bacterial strain, cell strain and vectors  
2.1.2 shRNA sequences 
WRN  
5’-TGAAGAGCAAGTTACTTGA-3’ (Cheng et al., 2006) 
Nbs1  
5’-GGGAGAAATGTGAATTCAAACGTGTGCTGTCCGTTGAGTTCACGTTTC- 
TTCCTTTTT-3’ (Zhong et al., 2007) 
 
2.1.3 Chemicals and reagents 





2.1.4 Buffer, solution and gel 
Buffer, solution and gel were prepared according to the formulation listed in 
Appendix II.  
 
2.1.5 Commercial kits 
The major commercial kits used in this research are listed in Appendix III. 
 
2.1.6 Equipments and facilities used 
All equipments and facilities were provided by Department of Nutrition and Food 
Science, University of Maryland, College Park and United States Department of 
Agriculture. The inventory is shown Appendix IV.  
 
2.1.7 Growth medium 
The growth medium used in this research is listed in Appendix V.  
 
2.2 Methods 
2.2.1 Transformation of the plasmid into DH5α competent cell 
 
The plasmid was obtained from lab and dissolved in TE buffer (Promega) with a 





The competent cell was prepared using a protocol modified from a standard 
procedure (Sambrook et al., 1989). DH5a was inoculated into 5 ml LB medium and 
shaken at 250 rpm, 37 ℃ overnight to obtain a starter culture. On the next day, 4 ml 
starter culture was added to 400 ml LB medium and grew until optimal density 600 
nm (O.D. 600) reached 0.4. The culture was chilled on ice for 10 min and centrifuged 
at 1600 g for 7 min at 4℃. The cell pellet was washed once and suspended in 80 ml 
pre-chilled 60 mM CaCl2 solution. The suspension was chilled on ice for 30 min and 
then centrifuged at 1100g for 5 min at 4 ℃. Finally, the pellet was resuspended in 8 
ml pre-chilled 60 mM CaCl2 solution. Aliquots of 200 µl were transferred into sterile 
1.5 ml microfuge tubes and stored at -80℃ for use. 
 
Right before transformation, -80 ℃ competent cell stock was thawed on ice. A total 
200ng plasmid DNA was added to 100 µl competent cells. The mixture was kept on 
ice for 20 min and subjected to a heat shock at 42 ℃ for 2 min. The cells were 
immediately rescued by adding 0.5 ml LB medium and incubation at 37 ℃ for 1 
hour with shaking at 300 rpm. The resuspension was evenly spread on LB agar plate 
supplemented with 100 µl/ml ampicillin and incubated at 37 ℃ overnight.  
 





White colonies were identified as positive recombinants. Positive recombinants were 
inoculated into 5 ml LB medium with shaking at 250 rpm, 37 ℃ overnight for the 
purpose of plasmid preparation. Plasmid DNA was isolated using the 
PureYieldTM plasmid Maxiprep System (Promega). The procedures were according to 
the manufacturer’s manual.  
 
2.2.3 Culturing, stocking and initiating U-2 OS cells. 
 
All U-2 OS cells were cultured in DMEM medium 37 ℃  and 5% CO2 in an 
incubator. Medium was changed every three days or when cells were 100% confluent. 
To obtain a stock, the DMEM medium was aspirated the cells were ashed with 10% 
PBS once. Trypsin was then added into cells and cells were kept at 37 ℃ for trypsin 
digestion. After 5 min, culture medium was added into digested cells to stop 
enzymatic reaction. A cell suspension was obtained here for protein extraction, flow 
cytometric analysis or stocking. 150 µl DMSO was added into aliquots of 1.5 ml 
medium and mixed well. The mixture was immediately transferred to a stock box 
filled with 2-proponol at -80 ℃ overnight. The cell stocks were then kept in liquid 
nitrogen tank for storage.  Upon initiation, the cell stocks were thawed at 37 ℃ in 
water bath and then centrifuged at 5000 rpm for 5min. The DMSO and medium 
mixture was poured out and fresh DMEM medium was added. After pipetting up and 





2.2.4 Transfection of U-2 OS cell 
 
WRN and WRN control cell lines were obtained from the cell line stock of Cheng lab. 
These two lines were established according to Cheng et al.'s paper (Cheng et al., 
2006). 
 
This protocol was modified from the Qiagen's manual. Approximately 8×105 of WRN 
or WRN control cells were seeded into a 60mm dish in 5 ml of DMEM growth 
medium with 1:250 supplemented Hygromycin B. The cells were incubated at 37 ℃ 
and 5% CO2 in an incubator overnight to reach 80% confluent. On the day of 
transfection, 3µg of plasmid DNA in TE buffer was added into DMEM medium 
without FBS and antibiotics to a final volume of 150 µl. Another 25 µl of PolyFect 
Transfection Reagent (Qiagen) was added. The mixture was vortexed for 10 sec and 
incubated at room temperature for 10 min to allow complex formation. Meanwhile, 
the DMEM medium was aspirated from the 60mm dishes and the cells were washed 
with 2 ml 10% PBS once. 3 ml DMEM medium was then added into the dishes. 1 ml 
DMEM medium was added into the reaction tube and mixed well. The mixture was 
immediately transferred to the 60 mm dishes. Puromycin was added into the total 
volume of the growth medium to a concentration of 0.4 µg/ml. The dishes were 
swirled gently to ensure even distribution of the complexes. The cells w re then 





2.2.5 Screening of the right recombinants 
 
Recombinants were incubated in DMEM medium supplemented with 0.4 µg/ml 
puromycin at 37 ℃ and 5% CO2 in an incubator for 1 week to allow gene expression. 
When the non-recombinants were killed by puromycin, 500 living cells were s eded 
per 100 mm dish to form single colonies. After two weeks, single co onies were 
isolated and harvested by clone rings. Monoclones were seeded onto 6 well plates 
while Hygromycin B and puromycin were used alternately in DMEM medium to 
maintain a selection pressure. After about 1 month, recombinants were enough in 
number to be screened by Western blotting analysis.  
 
This Western blotting protocol was modified from the abcam's manual. The cells 
were prepared according to 2.2.1 to form a cell suspension. The suspension was then 
transfered into 2 ml tube and centrifuged at 3,000 rpm and 4 ℃ for 5 min. The 
supernatant was discarded and 1 ml of 10% PBS was added to wash. The uspension 
was again centrifuged at 3,000 rpm and 4 ℃  for 5 min. The supernatant was 
aspirated completely and an ice chilled lysis mix consisting of 100 µl lysis buffer, 0.5 
µl PMSF and 2 µl 50X proteinase inhibitor solution was added. After pipetted up and 
down several times, the reaction mix was placed on ice for 15 min and centrifuged at 
20,000 g and 4℃ for 20 min. The supernatant containing protein was aspirated and 





To determine the protein concentration, a mixture of BCATM protein assay reagent A 
(100 µl), B (2µl) and protein solution (5 µl) was place at 37 ℃ for 30 min to allow 
the reaction to happen. The concentration was then analyzed by a FLUOstar 
OPTIMA microplate reader. 
 
25 µg protein from each sample was mixed with 5×loading buffer and 2-
mercaptoethanol (5% of loading buffer). The mixture was boiled at 95℃ for 5 min 
to denature the protein. The denatured protein was then added into CriterionTM 
precast gel for electrophoresis at 200 volts for 50 min. After the electrophoresis, the 
gel was placed in ice cold transfer buffer for 3 min to equilibrate.  A PVDF transfer 
member was cut into appropriate size and soaked in methanol for 2 min. The gel and 
PVDF transfer member were then sandwiched between sponge and paper after 
ensuring no air bubbles formed between the layers. The sandwich was submerged 
into pre-chilled transfer buffer at 100 volts for 1 hour. The member was rinsed by 
TBS-T once and submerged in blocking buffer to prevent non-specific binding for 1 
hour at room temperature under agitation. 
 
The member was rinsed for 5 min three times in TBS-T at room temperature then 
incubated with primary antibody at 4 ℃ overnight. The Nbs1 antibody was diluted 
into blocking buffer at a ratio of 1:1,000. The WRN and Tublin antibody were both 
diluted into blocking buffer at a ratio of 1:5,000.  After overnight incubation, the 
member was rinsed for 10 min, three times in TBS-T then incubated with secondary 




diluted into blocking buffer at a ratio of 1:1,0000. After that, the member was rinsed 
for 10 min, three times in TBS-T then incubated with SuperSignalTM 
Chemiluminescent Substrate for signal detection. X-ray films and automated x-ray 
developer were used here. 
 
2.2.6 Cell Survival assay 
 
5,000 cells of each cell line were seeded onto 6-well plates cultured in DMEM 
medium corresponding antibiotics (Hygromycin B or Puromycin) 37 ℃ and 5% CO2 
in an incubator. After 6 days, cells were resuspended according to 2.2.3 and counted 
using a hemocytometer. A total three trials were conducted and each trial consisted of 
3 repeats. 
2.2.7 Cell cycle progression assay 
 
All treatments were applied when cells reached 30% confluent. For CPT treatment, 
CPT was added into the medium to a final dilution of 1 µM. The cells were subject to 
treatment for 3 hours. The medium was then aspirated and the cells were rinsed in 
PBS once. Fresh medium was added afterwards to restore cell growth at 37 ℃ and 
5% CO2 in an incubator. Cells were harvest according to 2.2.3 at 0, 4, 8, 16, 24 or 48 
hours after removal of treatment.  
 
For HU treatment, HU was added into the medium to a final dilution of 0.5 mM. The 




cells were rinsed in PBS once. Fresh medium was added afterwards to restore cell 
growth at 37 ℃ and 5% CO2 in an incubator. Cells were harvest according to 2.2.3 
at 0, 2, 4, 8 or 24 hours after removal of treatment.  
 
For Aph treatment, Aph was added into the medium to a final dilution of 1 µg/ml. 
The cells were subject to treatment for 24 hours. The medium was then aspirated and 
the cells were rinsed in PBS once. Fresh medium was added afterwards to restore cell 
growth at 37 ℃ and 5% CO2 in an incubator. Cells were harvest according to 2.2.3 
at 0, 4, 6, 8 or 16 hours after removal of treatment.  
 
The harvested cells were centrifuged at 1,500 rpm for 5 min at 4 ℃. The supernatant 
was discarded and the pellet was washed with cold PBS once. The suspension was 
centrifuged at 1,500 rpm for 5 min at 4 ℃. The supernatant was discarded but about 
200 µl PBS was kept in the tube. The cells were pipetted up and down several times 
to be resuspended into single cell forms. 3 ml cold (-20℃) 70% ethanol was added 
dropwise into the cell suspension while vortexing. The cells were stora  -20 ℃ for 
staining. 
 
Upon staining, the cells were spinned down at 1,500 rpm for 5 min at 4 ℃. The 
supernatant was discarded and the pellet was washed with cold PBS once. The 
suspension was centrifuged at 1,500 rpm for 5 min at 4℃. The supernatant was 




containing RNase was added and the mixture was incubated in dark for 1 hour at 
room temperature using the Cellular DNA Flow Cytometric Anaylysis Reagent Set 
according to the manufacturer's manual. The mixture was scanned by a FACSCaliber 
Flow Cytometer (BD Biosciences) with program Cell Quest Pro. Cell cycle modeling 
was performed using ModFit (Verity). 




Chapter 3: Results 
 
3.1 Establishing positive Nbs-1 knockdown recombinants 
 
3.1.1 Nbs1 expression levels of positive recombinants 
Western blotting analysis was used here to confirm positive recombinants obtained 





Figure 3.1 Western blotting analysis of the expression profile of the Nbs1 gene in 
four cell lines. Tublin expressions were used as control. NC: Nbs1/WRN control; 
NW: Nbs1/WRN; C: WRN control; W: WRN.  
 
According to Western Blotting result, Nbs1 expression was successfully decreas d in 








3.1.2 Morphology of positive recombinants 
Pictures were taken for the cells under optic microscope when the four lines of cell
reached about 40% confluent. The magnification was 20x. 
 
Figure 3.2 WRN (W) cells. They are compact and in a regular rectangular form like 






Figure 3.3 WRN control (C) cells. These cells are inflated and extending their 






Figure 3.4 Nbs1/WRN (NW) cells. They are compact and in a regular rectangular 






Figure 3.5 Nbs1/WRN control (NC) cells. These cells are even bigger and more 
expanded. Their member is so extended outwards to form a very sharp shape of spear.  
 
It is very obviously that W and NW cells are quite similar in shape. They are compa t 
and in a regular rectangular form.  C cells, however, are inflated and extending their 
membrane to each other to form synapse like pointing whereas NC cells are even 
bigger and more expanded. Their member is so extended outwards to form a very 




3.2 Cell Survival assay 
Cell survival assay was conducted in accordance with 2.2.6. 
 Trial 1 Trial 2 Trial 3 Average 
W 55666.67 50666.67 58333.33 54888.89 
C 20333.33 19333.33 16666.67 18777.78 
NW 60833.33 50000 64000 58277.78 
NC 11666.67 16000 16166.67 14611.11 
 
Table 3.1 Cell number after 6 days of growth. NC: Nbs1/WRN control; NW: 
Nbs1/WRN; C: WRN control; W: WRN.  
 


















Figure 3.6 Cell number after 6 days of growth. NC: Nbs1/WRN control; NW: 





Two cell lines: W and NW grew at similar speed. The number rose from 500 in the 
beginning to about 50,000 to 60,000 in the end. However, another two lines, C and 
NC, although growing at similar speed as each other, only reach less than 20,000 cells 
after 6 days, which were 1/3 to ¼ of the numbers of W and NW. 
3.3 Flow Cytometric Analysis 
 
3.3.1 CPT treatment 






























































































Figure 3.7 Column chart showing quantification of cell cycle profile of CPT 




By 0 h after treatment, all four lines displayed similar pattern. The majority of cells 
were arrested at G0/G1 phase. By 4 h after treatment, a portion f cells progressed 
into S phase while all four lines still showed similar pattern. By 8 h after treatment, 
more cells of the four lines were in S phase than those in G0/G1 phase. By 16 h after 
treatment, cells began to show difference in progression pattern. Most C cells were 
still arrested in S phase while almost half of W cells appeared t G2/M phase. NW 
and NC cells left S phase at a speed faster than C cells but slower than W cells. By 24 
h after treatment, far less W cells were still arrested in S phase than the other three 




3.3.2 HU treatment 





















































































Figure 3.8 Column chart showing quantification of cell cycle profile of HU treatm nt 
(n=3). NC: Nbs1/WRN control; NW: Nbs1/WRN; C: WRN control; W: WRN. 
 
By 0 h after treatment, all four lines displayed similar pattern although most NC cells 
appeared at G0/G1 phase. The majority of cells were arrested at G0/G1 and S phase. 
By 2 h after treatment, most cells progressed into S phase whil all four lines still 
showed similar pattern. By 4 h after treatment, cells began to show difference in 
progression pattern. Most C, NW and NC cells were still arrested in S phase while 
almost half of W cells appeared at G2/M phase. Compared to the 2 h chart, the 
change in W cells was most obvious and great. NW and NC cells entered G2/M phase 
at a speed even slower than C. By 8 h and 24 h after treatment, the four lines 





3.3.3 Aph treatment 



























































































Figure 3.9 Column chart showing quantification of cell cycle profile of Aph treatm nt 
(n=3). NC: Nbs1/WRN control; NW: Nbs1/WRN; C: WRN control; W: WRN.  
 
By 0 h after treatment, all four lines displayed similar pattern that the majority of cells 
appeared at G0/G1 and S phase. By 4 h after treatment, most cells progressed and 
were arrested in S phase while all four lines still showed similar pattern. By 6 h after 
treatment, cells began to show difference in progression pattern. Most C and W 
progressed into G2/M phase at a similar speed while NC and NW cells were still 
arrested in S. By 8 h and 16 h after treatment, the four lines displayed similar profiles 
again. 
 
Chapter 4: Discussion 
4.1 Role of WRN and Nbs1 protein in the promotion of tumor cell growth 
Inhibition of WRN expression was reported to strongly impair growth of several 




carcinoma and endometrial leiomyosarcoma but excluding U-2 OS cells (Opresko et 
al., 2007). Given the bifunctional nature, WRN protein is proposed to promote cell 
proliferation by reducing DNA damage and replicative stress. This function of WRN 
also benefits the growth of oncogenic cells. Interestingly, it was suggested in another 
research that restoration of WRN expression had tumor suppressing effect. The loss 
of WRN function was thought to activate alternating lengthening of telomerase 
(ALT) mechanism and this mechanism exists commonly in sarcomas and induces 
tumor formation in mouse models (Agrelo et al., 2006). 
 
The result of this research study supports the latter hypothesis t at WRN protein has 
cancer suppressor properties. The two lines with WRN gene knocked down gre  at 
least 3-fold faster than the two lines with normal WRN expression. Considering that 
the WRN protein acts as intermediates in DNA replication, telomre maintenance and 
DNA damage response, loss of WRN function may trigger chromosomal aberration 
that is relevant to cancer. 
 
Another more interesting result of this research study is that Nbs1 could be 
significantly knockdown in WRN cells whereas a complete knockdown f Nbs1 in 
WRN control cells was somehow lethal. Only NC cells with Nbs1 partially knocked 
down could be viable and thus obtained in this study. In a similar study, i  was 
reported that knockdown of Nbs1 inhibited ATL mechanism in human fibrosarcoma 
cell line (Zhong et al., 2007). It was also reported in this paper that incomplete 




why only NC cells with incomplete Nbs1 knockdown were obtained. However, why 
Nbs1 was nearly completely knocked down in NW cells remains a question. Since 
enzymatic activities of WRN are needed to suppress telomeric-circle formation in 
normal cells which express telomerase reverse transcriptase (Li et al., 2008). Loss of 
WRN function might remediate the ATL mechanism in pathways different from Nbs1 
pathway so that ALT activity was still retained in NW cells even while Nbs1 was 
completely knocked down. Further research is needed to study the differnt pathways 
of WRN and Nbs1’s correlation with ALT mechanism. 
 
4.2 WRN and Nbs1 participate in S-phase checkpoint 





















Figure 4.1 Role of WRN and Nbs1 in S-phase checkpoint. The four cell lines were 
treated with CPT (1 µM, 3 h). Cells were harvested at the indicated time points and 
analyzed by flow cytometry (n=1). NC: Nbs1/WRN control; NW: Nbs1/WRN; C: 
WRN control; W: WRN. 
 
W and C cells displayed the same cell cycle profiles as were described in Cheng et
al.’s paper (Cheng et al., 2008). These date confirms that WRN plays a role in the S-
phase checkpoint induced by replication dependent DSBs. The fact that NC 
progresses into G2/M phase faster than C cells also confirms that notion that the 
MRN complex and ATM are interdependent in recognizing and signaling DNA DSBs 
(Berkovich et al. 2007). However, NW cells enter G2/M phase much slower than W 
cells and are at a similar speed as NC cells may indicate th  Nbs1, compared to 
WRN, is a more critical protein in sensing DSBs and plays a role as a bottle neck. 

















on Nbs1 because a complete depletion of Nbs1 increases ATM activation instead of 
decreasing it. 
4.2.2 HU treatment 
 
 
Figure 4.2 Role of WRN and Nbs1 in S-phase checkpoint. The four cell lines were 


























analyzed by flow cytometry (n=3). NC: Nbs1/WRN control; NW: Nbs1/WRN; C: 
WRN control; W: WRN. 
 
After HU treatment, W and C cells displayed the same cell cycle profiles as were 
described in Cheng et al.’s paper (Cheng et al., 2008). By 4 h after treatment, more 
than half of W cells entered G2/M phase while the majority of C cells were still 
arrested in S phase. Like CPT treatment, this date also confirms that WRN plays a 
role in the S-phase checkpoint induced by replication dependent DSBs. However, the 
two Nbs1 knockdown lines NC and NW were still arrested by 4 h after treatment, 
which, combined with data from CPT treatment, further confirms that t t ATM 
activation by WRN is not dependent on Nbs1 because a complete depletion of Nbs1 
increases ATM activations in both lines instead of decreasing them. It could be 
explained in both treatment that a partial depletion of Nbs1 in NC cells doesn’t affect 
ATM activation substantially. However it is not logical that a large number of NW 
cells are arrested in S phase because ATM is bound to the MRN complex via Nbs1. 
With a total completion of Nbs1, it is hard to explain why ATM could still be 








Figure 4.3 Role of WRN and Nbs1 in S-phase checkpoint. The four cell lines were 
treated with Aph (1 µg/ ml, 24 h). Cells were harvested at the indicated time points 
and analyzed by flow cytometry (n=3). NC: Nbs1/WRN control; NW: Nbs1/WRN; 




























After Aph treatment, W and C cells displayed the same cell cyc e kinetics as were 
described in Cheng et al.’s paper (Cheng et al., 2008) showing that WRN only 
participates in S phase checkpoint induced by replication-dependent DSBs. However, 
the two Nbs1 knockdown lines NC and NW were still arrested by 6 h after treatment, 
which, considering the treatment of Aph as a DNA polymerase inhibition, Nbs1 may 
participate other cell cycle checkpoints induced by Aph stress which is different from 
DSBs. There is evidence showing that it is Mre11 binding domain instead of 
FHA/BRCT domains of Nbs1 taking part in the efficient induction of the intra-S 
checkpoint (Stewart et al., 2003; Goldberg et al., 2003). G1 and G2 checkpoints may 
also involve Nbs1 (Kobayashi et al., 2004). However reports are controversial and the 
mechanism behind them remains unsolved, more investigation needs to be done. 
 
4.3 Conclusion and prospect 
Previous study showed that WRN protein was involved in ATM pathway activation 
when cells are exposed to DSBs induced by replication fork collapse. Because the 
Mre11-Rad50-Nbs1 (MRN) complex, a sensor of DSBs, is known to interact with 
WRN and ATM via Nbs1 subunit, we are interested in whether the MRN complex 
mediates the WRN-dependent ATM pathway activation.  In this study, we employed 
short-hairpin RNA to generate WRN- and Nbs1-deficient U-2 OS cells and treat cells 
with clastogens which induce collapsed replication forks, thus provided primary proof 




cell survival assay on all cell lines, hoping to get auxiliary information on the 
function of these two target proteins. Upon analyzing our results, we concluded that: 
 
1. The result of this research study supports the hypothesis that WRN protein has 
cancer suppressor properties by affecting ATL mechanism. Nbs1, on the other hand, 
also affects the ATL mechanism in a way that is different from WRN pathways. 
 
2.  Our data suggest that ATM activation by WRN is not dependent on Nbs1 although 
ATM interacts with both WRN and the WRN complex. 
 
Our ultimate task is to understand aging as well as the relationship between cell cycle 
checkpoints and genomic stability by studying protein-protein interac ion. Thorough 
understanding on the novel WRN-dependent ATM activation will shed light on some 
unknown cellular network. To achieve this goal, there are works left to be done in 
future. 
 
Zhong et al., used a scrambled control shRNA sequence to make a control pCIpur 
vector (Zhong et al., 2007). As a result, both Nbs1 deficient and control cell line all 
grew under puromycin condition. We did not obtain the control plasmid so the W and 
C cell lines we used as control were cultured only under hygromycin B without 
puromycin pressure. Meanwhile the NC and NW cell lines were under the pressure of 




better to repeat all the experiments using a control plasmid so that all four cell lines 
are cultured under the same condition. 
 
FACS data only provide indirect information on ATM activation. ATM 
autophosphorylation on Ser-1981 needs to be quantified by Western Blotting using 
the four cell lines after treatment according to 2.2.7. Downstream ATM pathway 
should also been analyzed to further support ATM activation. ATM substrate  like 
SMC1, BRCA1 and CHK1 could be tested by Western Blotting on 
autophosphorylation. Besides Western Blotting assay, immunostaining could also be 
used to confirm ATM phosphorylation according to the protocol described in Cheng 
et al.’s 2008 paper.  
 
Protein colocalization could be tried either under stress or without stress by 
performing coimmunofluorescence. The data could also be used to know at which 
cell cycle phase when proteins interact with each other. 
 
In order to confirm that DSB formation exist in all four cell lines. Assays on γH2AX 
formation also need to be performed to show whether DSB formation are i hibited by 
gene expression knockdown. 
 
Our data bring question on Nbs1’s role on other cell cycle checkpoints. A  analysis 




kinetics of cell replication under different treatment could be compared to investigate 






Appendix I: Chemicals and reagents 
2-Mercaptoethanol Sigma M3148 
2-Propanol Fisher A451-4 
10XTBS Bio-Rad 170-6435 
10XTG Bio-Rad 161-0771 
10XTBS Bio-Rad 170-6435 
10% SDS Teknova S0184 
ampicillin Sigma A-9518 
aphidicolin Calbiochem 178273 
camptothecin MP Biomedicals IC15973250 
DMEM,1X Cellgro 10-017-CV 
DMSO Sigma D5897 
Ethanol (absolute) Merck 100986 
EDTA Quality Biological 351-027-10 
Fetal Bovine Serum Atlanta S11550 
Glycerol Sigma G-5516 
hydroxyurea MP Biomedicals AAAL01120-03 
hygromycin B Invitrogen A98670309 
KCl Baker 4001-01 
KH2PO4 Baker 4008-01 
LB Agar, Miller Fisher BP1425-500 
LB Broth Fisher BP1426-500 
Methanol Fisher A452-4 
NaCl Baker 4058-05 
Na2 hPO4 Sigma S-7907 
Non-Fat Dry Milk Bio-Rad 170-6404 




Penicillin-Streptomycin Cellgro 30-002-CI 
Precision Plus ProteinTM KaleidoscopeTM 
Standards 
BIO-RAD 161-0375 
Protease inhibitor cocktail tablets Complete 11697498001 
Puromycin Calbiochem 540222 
Tris-HCl Quality Biological 351-007-101 
Trypsin EDTA, 1X Cellgro 25-052-C 
Tween20 Calbiochem 655204 
 
 
Appendix II: Buffer, solution and gel 
5X loading buffer  
50X proteinase inhibitor solution 
1 Protease inhibitor cocktail tablet, 1 mL 
1XPBS 
10X PBS 
80 g NaCl, 10 g KCl, 72 g Na2 hPO4, 12 g 
KH2PO4, 1 L dd H20 
Cell culture medium  
500 mL DMEM medium, 50 mL Fetal 
Bovine Serum, 5 mL Penicillin-Streptomycin 
Blocking buffer 5 g Non-Fat Dry Milk, 100 mL TBS-T 
LB broth 25 g/L LB powder, autoclave 
LB agar plate 40 g/ L LB Agar, Miller, autoclave 
Lysis buffer 
50 mM Tris-HCl (7.4), 250 mM NaCl, 5 mM 
EDTA, 0.1% NP40 
Protein gel CriterionTM Precast Gel 345-0033 
Running buffer 100 mL 10XTGS, 900 mL ddH20 
TBS-T 
100 mL 10XTBS, 900 mL ddH20, 10 mL 
10% Tween20 
Transfer buffer 
700 mL ddH20, 100 mL 10XTG,200 mL 





Appendix III: Commercial kits 
BCATM Protein Assay Kit Thermo JI124811 
PolyFect® Transfection Reagent Qiagen 301107 
PureYieldTM Plasmid Maxiprep System Promega A2393 
SuperSignal® West Pico Chemiluninescent Substrate Thermo IF113677 
SuperSignal® West Femto Maximum Sensitivity Substrate Thermo IF129579 
 
Appendix IV: Equipments and facilities used 
Balance Denver Instrument S-403 
Biological Safety Cabinet Thermo 109578 
CO2 incubator Thermo 3595 
FLUOstar OPTIMA BMG 413-3128 
Isotemp Air Bath Fisher 11-715-1250 
Isotemp Water Bath Fisher 15-462-01 
Legen RT centrifuge Thermo 75004377 
Optic Microscope Motic AE21 
PowerPacTM HC Bio-Rad 043BR18642 
Rocker VWR 12620-906 
Roto-Shake Genie Scientific Industries S1-1100 
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